SCM
ATYR

Stonepine Capital Management’s aTyr Pharma ATYR Stock Holding History

Stonepine Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-482,258
Closed -$680K – 24
2023
Q4 		$680K Sell
482,258
-4,144,366
-90% -$5.32M 0.29% 16
2023
Q3 		$7.31M Sell
4,626,624
-600
-0% -$1.11K 2.43% 10
2023
Q2 		$9.99M Sell
4,627,224
-198,498
-4% -$433K 3.61% 9
2023
Q1 		$10.1M Buy
+4,825,722
New +$10.6M 3.4% 9
2022
Q4 		– Sell
-600,980
Closed -$1.8M – 24
2022
Q3 		$1.8M Sell
600,980
-600
-0.1% -$2.01K 0.81% 16
2022
Q2 		$1.7M Hold
601,580
– – 0.79% 20
2022
Q1 		$3.22M Buy
601,580
+76,049
+14% +$431K 1.33% 16
2021
Q4 		$3.93M Buy
525,531
+114,996
+28% +$960K 1.8% 13
2021
Q3 		$3.73M Buy
+410,535
New +$2.46M 1.7% 14

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stonepine Capital Management's ATYR Position: Q1 2024 in Review

Stonepine Capital Management sold out of aTyr Pharma (ATYR) in Q1 2024, closing a stake of 482,258 shares — an estimated $680K sold.

Stonepine Capital Management first reported a position in ATYR in Q3 2021 and held it in 9 quarters. The position peaked at $10.1M in Q1 2023. 56 funds tracked by Wall St. Rank hold ATYR as of Q1 2024.

  • Stonepine Capital Management reported no remaining aTyr Pharma position as of Q1 2024 after selling out during the quarter.
  • Stonepine Capital Management sold 482,258 aTyr Pharma shares in Q1 2024, an estimated $680K.
  • Stonepine Capital Management first reported a position in aTyr Pharma in Q3 2021 and held it in 9 quarters.
  • Stonepine Capital Management's aTyr Pharma position peaked at $10.1M in Q1 2023.
  • 56 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2024.

Based on Stonepine Capital Management's 13F filing for Q1 2024, filed 15 May 2024.